One-year recurrence rate of Graves ophthalmopathy presenting as diplopia in the primary position after varied doses of intravenous methylprednisolone followed by oral prednisolone with dosing based on the magnetic resonance imaging findings.
Diplopia
Graves ophthalmopathy
Intravenous methylprednisolone
Magnetic resonance imaging
Recurrence rate
Journal
Japanese journal of ophthalmology
ISSN: 1613-2246
Titre abrégé: Jpn J Ophthalmol
Pays: Japan
ID NLM: 0044652
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
16
02
2022
accepted:
25
08
2022
pubmed:
28
10
2022
medline:
28
1
2023
entrez:
27
10
2022
Statut:
ppublish
Résumé
To reveal the recurrence rate of Graves ophthalmopathy (GO) presenting as diplopia in the primary position for 1 year after varied doses of intravenous methylprednisolone (IVMP) followed by oral prednisolone, with dosing based on the magnetic resonance imaging (MRI) findings. Retrospective study. We analyzed the medical charts of 25 patients who were diagnosed with new-onset GO and who received treatment for diplopia in the primary position at our hospital. Treatment consisted of MRI-determined varied doses of IVMP followed by oral prednisolone. If the MRI findings showed deterioration or were unchanged after 6 g of IVMP, 3 g of IVMP was added for further treatment. Simple and multiple linear regression analyses were performed to reveal the associations between the independent variables and the dependent variable, defined as recurrence. The mean patient age (± standard deviation) was 61.3 ± 11.3 years. The female to male ratio was 15:10. Twenty-one of the 25 patients received a total of 6 g of IVMP, whilst the remaining 4 patients received a total of 9 g of IVMP. In 5 patients (20%), the GO recurred within 1 year of IVMP administration. Simple and multiple linear regression analyses showed that the MRI findings after 6 g of IVMP affected recurrence (P < .05). This study showed that in 20% of patients, GO recurred within 1 year of administration of varied doses of IVMP, with the dosing based on the MRI findings. Furthermore, assessment of inflammation by use of MRI after 6 g of IVMP has a potential role in predicting recurrence.
Identifiants
pubmed: 36301447
doi: 10.1007/s10384-022-00954-9
pii: 10.1007/s10384-022-00954-9
doi:
Substances chimiques
Methylprednisolone
X4W7ZR7023
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
91-96Informations de copyright
© 2022. Japanese Ophthalmological Society.
Références
Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020;16:104–16.
doi: 10.1038/s41574-019-0305-4
Ohtsuka K, Sato A, Kawaguchi S, Hashimoto M, Suzuki Y. Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves’ ophthalmopathy. Jpn J Ophthalmol. 2002;46:563–7.
doi: 10.1016/S0021-5155(02)00544-0
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European thyroid association/European group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016;5:9–26.
doi: 10.1159/000443828
Tsirouki T, Bargiota A, Tigas S, Vasileiou A, Kapsalaki E, Giotaki Z, et al. Clinical and imaging evaluation of the response to intravenous steroids in patients with Graves’ orbitopathy and analysis on who requires additional therapy. Clin Ophthalmol. 2016;10:2277-89.
Higashiyama T, Nishida Y, Ohji M. Relationship between magnetic resonance imaging signal intensity and volume of extraocular muscles in thyroid-associated ophthalmopathy with methylprednisolone pulse therapy. Clin Ophthalmol. 2016;10:721–9.
doi: 10.2147/OPTH.S105096
Higashiyama T, Nishida Y, Morino K, Ugi S, Nishio Y, Maegawa H, et al. Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy. Jpn J Ophthalmol. 2015;59:124–30.
doi: 10.1007/s10384-014-0365-x
Kahaky GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90:5234–40.
doi: 10.1210/jc.2005-0148
Bartalena L, Martino E, Marcocci C, Bogazzi F, Panicucci M, Velluzzi F, et al. More on smoking habits and Graves’ ophthalmopathy. J Endocrinol Invest. 1989;12:733–7.
doi: 10.1007/BF03350047
Prummel MF, Wiersinga WM. Smoking and risk of Graves’ disease. JAMA. 1993;269:479–82.
doi: 10.1001/jama.1993.03500040045034
Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell’Unto E, Bartolomei NP, et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med. 1998;129:632–5.
doi: 10.7326/0003-4819-129-8-199810150-00010
Noh JY, Hamada N, Abe Y, Ito K, Ito K. Thyroid-stimulating antibody is related to Graves’ ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves’ disease. Thyroid. 2000;10:809–13.
doi: 10.1089/thy.2000.10.809
Rajendram R, Bunce C, Adams GGW, Dayan CM, Rose GE. Smoking and strabismus surgery in patients with thyroid eye disease. Ophthalmology. 2011;118:2493–7.
doi: 10.1016/j.ophtha.2011.06.003